Genmab A/S (GNMSF) Income Statement Analysis

See more : BioNxt Solutions Inc. (BNXT.CN) Income Statement Analysis – Financial Results

Complete financial analysis of Genmab A/S (GNMSF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Genmab A/S, a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Mountain Crest Acquisition Corp. III (MCAEU) Income Statement Analysis – Financial Results
Poppins Corporation (7358.T) Income Statement Analysis – Financial Results
KinderCare Learning Companies, Inc. (KLC) Income Statement Analysis – Financial Results
Manuka Resources Limited (MKR.AX) Income Statement Analysis – Financial Results
Honworld Group Limited (2226.HK) Income Statement Analysis – Financial Results

Genmab A/S (GNMSF)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.genmab.com

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002
Revenue	16.47B	14.60B	8.48B	10.11B	5.37B	3.03B	2.37B	1.82B	1.13B	850.39M	663.57M	484.64M	350.94M	582.08M	586.08M	745.11M	529.54M	135.55M	98.51M	4.10M	68.33M	0.00
Cost of Revenue	226.00M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	532.51M	582.51M	0.00	48.81M	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	16.25B	14.60B	8.48B	10.11B	5.37B	3.03B	2.37B	1.82B	1.13B	850.39M	663.57M	484.64M	-181.57M	-435.00K	586.08M	696.30M	529.54M	135.55M	98.51M	4.10M	68.33M	0.00
Gross Profit Ratio	98.63%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	-51.74%	-0.07%	100.00%	93.45%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%
Research & Development	7.63B	5.56B	4.18B	3.14B	2.39B	1.43B	874.28M	660.88M	487.66M	505.68M	527.58M	536.70M	532.51M	0.00	935.36M	1.42B	618.50M	359.95M	304.10M	373.33M	345.98M	396.23M
General & Administrative	0.00	0.00	0.00	661.00M	342.00M	213.70M	146.99M	102.41M	91.22M	79.53M	66.74M	64.61M	67.85M	160.25M	148.75M	143.53M	38.59M	37.11M	38.04M	72.04M	64.55M	86.85M
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	3.30B	2.68B	1.28B	661.00M	342.00M	213.70M	146.99M	102.41M	91.22M	79.53M	66.74M	64.61M	67.85M	160.25M	148.75M	143.53M	38.59M	37.11M	38.04M	72.04M	64.55M	86.85M
Other Expenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	10.93B	8.24B	5.46B	3.80B	2.73B	1.64B	1.02B	763.29M	402.66M	585.21M	594.32M	601.32M	67.85M	160.25M	1.08B	1.35B	966.67M	607.76M	526.43M	-437.17M	410.54M	440.17M
Cost & Expenses	11.15B	8.24B	5.46B	3.80B	2.73B	1.64B	1.02B	763.29M	402.66M	585.21M	594.32M	601.32M	600.36M	742.77M	1.08B	1.39B	966.67M	607.76M	526.43M	-437.17M	410.54M	440.17M
Interest Income	939.00M	324.00M	197.00M	184.00M	120.00M	62.92M	41.43M	32.58M	37.26M	38.33M	28.61M	17.83M	3.49M	1.40M	181.10M	126.67M	155.11M	46.25M	34.78M	42.52M	68.68M	53.39M
Interest Expense	27.00M	21.00M	13.00M	10.00M	7.00M	417.00K	2.80M	213.00K	118.00K	4.05M	3.33M	2.72M	43.09M	39.65M	25.05M	220.83M	1.15M	1.03M	1.35M	68.58M	83.71M	100.37M
Depreciation & Amortization	240.00M	290.00M	250.00M	246.00M	139.00M	87.70M	47.54M	40.96M	31.82M	12.33M	11.66M	15.11M	15.05M	21.03M	83.78M	85.09M	14.25M	17.50M	31.78M	53.66M	63.67M	47.47M
EBITDA	5.56B	7.04B	3.46B	6.76B	2.78B	1.47B	1.46B	1.09B	585.98M	277.51M	80.92M	-96.25M	-192.75M	-61.76M	-77.11M	-516.46M	-317.72M	-419.70M	-360.46M	537.46M	474.56M	669.75M
EBITDA Ratio	33.76%	48.26%	40.83%	66.82%	53.99%	50.60%	61.53%	62.02%	70.56%	37.14%	16.51%	-17.28%	-43.23%	-10.61%	-39.78%	-75.66%	-55.57%	-306.70%	-355.83%	13,105.49%	694.55%	0.00%
Operating Income	5.32B	6.36B	3.02B	6.31B	2.64B	1.38B	1.34B	1.05B	730.38M	265.18M	69.25M	-116.68M	-249.42M	-160.69M	-498.03M	-870.00M	-437.13M	-472.21M	-427.92M	441.27M	-342.21M	-483.08M
Operating Income Ratio	32.30%	43.56%	35.58%	62.44%	49.16%	45.63%	56.83%	57.97%	64.46%	31.18%	10.44%	-24.08%	-71.07%	-27.61%	-84.98%	-116.76%	-82.55%	-348.38%	-434.42%	10,760.13%	-500.85%	0.00%
Total Other Income/Expenses	316.00M	768.00M	1.03B	-409.00M	221.00M	232.00M	-280.45M	77.38M	27.15M	32.17M	-3.85M	2.60M	39.59M	38.25M	156.05M	-94.84M	53.76M	33.98M	34.33M	-26.06M	-15.03M	962.08M
Income Before Tax	5.64B	7.04B	3.98B	5.90B	2.86B	1.61B	1.06B	1.13B	757.53M	297.35M	65.40M	-114.08M	-209.83M	-122.44M	-341.99M	-964.51M	-383.37M	-438.24M	-393.59M	415.21M	327.18M	479.00M
Income Before Tax Ratio	34.22%	48.20%	46.96%	58.39%	53.28%	53.29%	44.97%	62.23%	66.86%	34.97%	9.86%	-23.54%	-59.79%	-21.04%	-58.35%	-129.44%	-72.40%	-323.31%	-399.56%	10,124.65%	478.85%	0.00%
Income Tax Expense	1.29B	1.51B	975.00M	1.15B	693.00M	139.83M	-39.83M	-56.86M	-5.99M	-3.95M	-4.75M	-2.63M	5.92M	20.87M	5.91M	583.00K	128.62M	38.99M	45.64M	872.94M	-66.00K	326.00K
Net Income	4.35B	5.45B	2.96B	4.76B	2.17B	1.47B	1.10B	1.19B	763.51M	301.30M	112.36M	-487.12M	-596.37M	-321.46M	-1.01B	-965.09M	-383.37M	-438.24M	-393.59M	-415.21M	-327.11M	-479.33M
Net Income Ratio	26.42%	37.36%	34.86%	47.06%	40.37%	48.66%	46.67%	65.36%	67.39%	35.43%	16.93%	-100.51%	-169.94%	-55.23%	-172.46%	-129.52%	-72.40%	-323.31%	-399.56%	-10,124.65%	-478.75%	0.00%
EPS	66.02	83.38	46.00	73.00	34.40	24.03	18.14	19.83	13.05	5.35	2.20	-10.58	-13.28	-7.16	-22.51	-21.62	-8.72	-11.26	-12.59	-15.69	-14.33	-21.46
EPS Diluted	66.02	82.59	45.54	72.22	34.04	23.72	17.77	19.22	12.56	5.26	2.16	-10.58	-13.28	-7.16	-22.51	-21.62	-8.72	-11.26	-12.59	-15.69	-14.33	-21.46
Weighted Avg Shares Out	65.92M	65.39M	65.40M	65.18M	62.96M	61.27M	60.83M	59.88M	58.52M	56.32M	50.98M	46.04M	44.91M	44.91M	44.90M	44.64M	43.94M	38.93M	31.25M	26.47M	22.83M	22.34M
Weighted Avg Shares Out (Dil)	65.91M	66.01M	66.05M	65.89M	63.64M	62.04M	62.09M	61.77M	60.77M	57.25M	51.91M	46.04M	44.91M	44.91M	44.90M	44.64M	43.94M	38.93M	31.25M	26.47M	22.83M	22.34M

Genmab (GMAB), AbbVie Lymphoma Candidate Gets Orphan Drug Tag

March 9, 2022zacks.com

Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for non-Hodgkin's lymphoma, follicular lymphoma. The FDA grants orphan drug status for the candidate as a treatment for FL.

Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma

February 24, 2022globenewswire.com

Media Release COPENHAGEN, Denmark, and BOTHELL, Wash., February 24, 2022

Genmab A/S (GMAB) CEO Jan van de Winkel on Q4 2021 Results - Earning Calls Transcript

February 16, 2022seekingalpha.com

Genmab A/S (GMAB) CEO Jan van de Winkel on Q4 2021 Results - Earning Calls Transcript

Genmab Announces that Janssen has Received Conditional European Marketing Authorization for RYBREVANT® (amivantamab) for Patients with Advanced Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations, after Failure of Platinum-base

December 13, 2021globenewswire.com

Media Release Copenhagen, Denmark, December 13, 2021

Genmab A/S (GMAB) CEO Jan van de Winkel on Q3 2021 Results - Earnings Call Transcript

November 10, 2021seekingalpha.com

Genmab A/S (GMAB) CEO Jan van de Winkel on Q3 2021 Results - Earnings Call Transcript

Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer

September 20, 2021businesswire.com

COPENHAGEN, Denmark & BOTHELL, Wash.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to TIVDAK™ (tisotumab vedotin-tftv), the first and only approved antibody-drug conjugate (ADC)...